Marktanalyse - Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

Global Markets Direct
03.2017
107 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia — Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Neutropenia (Oncology) pipeline landscape.

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 5, 8, 1, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Neutropenia - Overview

Chemotherapy Induced Neutropenia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chemotherapy Induced Neutropenia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development

Apotex Inc

Biocon Ltd

Biogenomics Ltd

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Cinfa Biotech SL

Dr. Reddy's Laboratories Ltd

Gene Techno Science Co Ltd

Generon (Shanghai) Corp Ltd

Genexine Inc

GlycoMimetics Inc

Hanmi Pharmaceuticals Co Ltd

Mycenax Biotech Inc

Myelo Therapeutics GmbH

Nohla Therapeutics Inc

Octapharma AG

Pfenex Inc

Pfizer Inc

Reliance Life Sciences Pvt Ltd

Richter Gedeon Nyrt

Sandoz International GmbH

USV Pvt Ltd

Chemotherapy Induced Neutropenia - Drug Profiles

BBT-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBT-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBT-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eflapegrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-627 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMI-1271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXG-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSA-GCSF - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myelo-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romyelocel-L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WBI-2100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YPEG-Filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Neutropenia - Dormant Projects

Chemotherapy Induced Neutropenia - Discontinued Products

Chemotherapy Induced Neutropenia - Product Development Milestones

Featured News & Press Releases

Feb 16, 2017: U.S. FDA Accepts Biologics License Application for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

Dec 05, 2016: Spectrum Pharmaceuticals Highlights Four Abstracts on ROLONTIS (eflapegrastim) at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016

Dec 02, 2016: Cinfa Biotech publishes clinical data abstract at the 58th American Society of Hematology Annual Meeting 2016

Sep 26, 2016: Cinfa Biotech starts second clinical study of pegfilgrastim biosimilar candidate B12019

Jul 04, 2016: Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019

Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer

Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco

Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm

May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia

Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia

Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China

May 10, 2011: Dr Reddy’s Launches Pegfilgrastim In India Under Brand Name Peg-grafeel

Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients

Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology

Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Ltd, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech SL, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Genexine Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2017

Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H1 2017

Chemotherapy Induced Neutropenia - Dormant Projects, H1 2017

Chemotherapy Induced Neutropenia - Dormant Projects, H1 2017 (Contd..1), H1 2017

Chemotherapy Induced Neutropenia - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus